BioCentury | Apr 9, 2015
Distillery Therapeutics

Therapeutics: Tripartite motif-containing 72 (TRIM72; MG53)

Renal disease INDICATION: Renal damage In vitro and rodent studies suggest MG53 could help prevent acute kidney injury (AKI). In renal cell-based models of mechanical or anoxic AKI, recombinant human MG53 localized to sites of...
BioCentury | Jun 28, 2012
Distillery Therapeutics

Indication: Musculoskeletal disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Muscular dystrophy Tripartite motif-containing 72 (TRIM72; MG53) In vitro and mouse studies suggest MG53 could help treat Duchenne muscular dystrophy...
BioCentury | Apr 11, 2011
Clinical News

Tarceva erlotinib: Additional Phase II data

Researchers at the M.D. Anderson Cancer Center reported additional data from a subgroup of 101 stage IV NSCLC patients who had gene expression profiles obtained from pretreatment core needle biopsies in the adaptive, open-label, U.S....
Items per page:
1 - 3 of 3